ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis protection, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and business highlights.
Participants can obtain dial-in information by registering for the event. The webcast and presentation slides will be accessible through the Events & Presentations page in the Investors & Media section of the company's website. A replay will remain available for 30 days after the event.
ARS Pharmaceuticals (NASDAQ: SPRY), un'azienda biofarmaceutica specializzata nello sviluppo di soluzioni per la protezione dall'anafilassi, ha programmato una conference call e una webcast per mercoledì 14 maggio 2025, alle 5:30 PT / 8:30 ET. L'evento presenterà i risultati finanziari del primo trimestre 2025 e i principali aggiornamenti aziendali.
I partecipanti possono ottenere le informazioni per il collegamento telefonico registrandosi all'evento. La webcast e le slide della presentazione saranno disponibili nella pagina Eventi e Presentazioni, nella sezione Investitori e Media del sito web aziendale. La registrazione resterà accessibile per 30 giorni dopo l'evento.
ARS Pharmaceuticals (NASDAQ: SPRY), una compañía biofarmacéutica enfocada en desarrollar soluciones para la protección contra la anafilaxia, ha programado una llamada de conferencia y webcast para el miércoles 14 de mayo de 2025 a las 5:30 a.m. PT / 8:30 a.m. ET. El evento cubrirá los resultados financieros del primer trimestre de 2025 y los aspectos destacados del negocio.
Los participantes pueden obtener la información para llamar registrándose en el evento. El webcast y las diapositivas de la presentación estarán disponibles en la página de Eventos y Presentaciones en la sección de Inversores y Medios del sitio web de la compañía. La repetición estará disponible durante 30 días después del evento.
ARS Pharmaceuticals (NASDAQ: SPRY)는 아나필락시스 보호 솔루션 개발에 주력하는 바이오제약 회사로, 2025년 5월 14일 수요일 오전 5:30 PT / 오전 8:30 ET에 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 이번 행사에서는 회사의 2025년 1분기 재무 실적과 주요 사업 하이라이트를 다룰 예정입니다.
참가자는 행사 등록을 통해 전화 접속 정보를 받을 수 있습니다. 웹캐스트와 발표 자료는 회사 웹사이트의 투자자 및 미디어 섹션 내 이벤트 및 프레젠테이션 페이지에서 확인할 수 있으며, 행사가 끝난 후 30일간 다시보기 서비스를 제공합니다.
ARS Pharmaceuticals (NASDAQ : SPRY), une société biopharmaceutique spécialisée dans le développement de solutions de protection contre l'anaphylaxie, a programmé une conférence téléphonique et une webdiffusion pour le mercredi 14 mai 2025 à 5h30 PT / 8h30 ET. L'événement portera sur les résultats financiers du premier trimestre 2025 et les points forts de l'activité de l'entreprise.
Les participants peuvent obtenir les informations d'appel en s'inscrivant à l'événement. La webdiffusion et les diapositives de présentation seront accessibles via la page Événements & Présentations dans la section Investisseurs & Médias du site web de la société. Une rediffusion sera disponible pendant 30 jours après l'événement.
ARS Pharmaceuticals (NASDAQ: SPRY), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Lösungen zum Schutz vor Anaphylaxie spezialisiert hat, hat eine Telefonkonferenz und Webcast für Mittwoch, den 14. Mai 2025, um 5:30 Uhr PT / 8:30 Uhr ET angesetzt. Die Veranstaltung wird die Finanzergebnisse des ersten Quartals 2025 und wichtige Geschäftshighlights behandeln.
Teilnehmer können die Einwahlinformationen durch Registrierung für die Veranstaltung erhalten. Der Webcast und die Präsentationsfolien sind über die Seite „Events & Presentations“ im Bereich „Investoren & Medien“ auf der Unternehmenswebsite zugänglich. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668
FAQ
When will ARS Pharmaceuticals (SPRY) report Q1 2025 earnings?
How can I access SPRY's Q1 2025 earnings call?
How long will the replay of ARS Pharmaceuticals' Q1 2025 earnings call be available?
What does ARS Pharmaceuticals (SPRY) specialize in?
